Caplyta receives additional FDA approval for new indication by end of 2025? | Binary | | | 2 days ago | |
Milestone payments for Eli Lilly's PI3Kα program by end of 2025? | Categorical | | | 2 days ago | |
Will Eli Lilly's PI3Kα program achieve a milestone payment by end of 2025? | Binary | | | 2 days ago | |
Will Eli Lilly complete acquisition of Scorpion's PI3Kα program by end of 2025? | Binary | | | 2 days ago | |
Company making largest biotech acquisition by end of 2025? | Categorical | | | 2 days ago | |
Regulatory body blocks J&J acquisition of Intra-Cellular Therapies by end of 2025? | Binary | | | 2 days ago | |
Next major biotech acquisition announcement by March 31, 2025? | Categorical | | | 2 days ago | |
Final acquisition price per share for Intra-Cellular Therapies? | Categorical | | | 2 days ago | |
Johnson & Johnson completes acquisition of Intra-Cellular Therapies by June 30, 2025? | Binary | | | 2 days ago | |
Number of combination therapy trials for Eli Lilly's PI3Kα inhibitor by end of 2025? | Categorical | | | 2 days ago | |
Objective response rate for Eli Lilly's PI3Kα inhibitor in trials by end of 2025? | Categorical | | | 2 days ago | |
Will Eli Lilly's PI3Kα inhibitor receive FDA approval by end of 2026? | Binary | | | 2 days ago | |
